Evestra Inc.
New delivery methods, new molecules for women’s health
This article was originally published in Start Up
Executive Summary
Evestra Inc. aims to leverage its managers’ and advisors’ understanding of steroid drugs, then amplify that with expertise in medicinal chemistry, polymer science, and drug delivery. The company thinks it has the potential to create multiple women’s health products based on vaginal ring devices and new chemical entities that could be potentially safer and more effective than known ones.
You may also be interested in...
Women’s Health: Moving Beyond Gynecology To Sexuality
Big Pharma’s exodus from women’s health has created opportunities for biotech start-ups, which hope to tap into potentially huge markets. Profiles of Evestra Pharmaceuticals, S1 Biopharma, and Sprout Pharmaceuticals.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.